Vitamin B3 can reduce skin cancer development, according to coverage from VA News (.gov), reviving dermatologic interest in nicotinamide as a low-cost chemoprevention strategy for patients at high risk of keratinocyte carcinomas.

The report centers on the role of vitamin B3 — specifically the amide form, nicotinamide — in modulating the cellular damage that ultraviolet radiation inflicts on skin. The Department of Veterans Affairs has a direct stake in this question: veterans represent a population with substantial cumulative sun exposure, and non-melanoma skin cancer remains the most frequently diagnosed malignancy within VA healthcare.

The VA News item frames the findings within a growing body of dermatologic literature on chemoprevention. Interest in nicotinamide stems from its mechanism: the molecule serves as a precursor to nicotinamide adenine dinucleotide (NAD+), a coenzyme depleted by UV exposure. Replenishing NAD+ supports DNA repair processes and bolsters the skin's cellular energy metabolism, two pathways critical to preventing the cascade of mutations that leads to actinic keratoses and, ultimately, squamous and basal cell carcinomas.

For dermatologists, the clinical appeal lies in the risk-benefit profile. Nicotinamide is available over the counter, inexpensive, and generally well tolerated — characteristics that distinguish it from more burdensome preventive interventions such as topical chemotherapy agents or procedural approaches to field cancerization. The VA's attention to the compound signals potential relevance for institutional protocols managing large cohorts of immunosuppressed or heavily sun-damaged patients, groups in which keratinocyte carcinoma incidence runs well above population averages.

The coverage arrives as dermatology continues to weigh where oral nicotinamide fits in the prevention armamentarium alongside established measures: daily broad-spectrum sunscreen use, routine skin examinations, and treatment of precursor lesions. No preventive agent replaces those fundamentals, and the VA report does not suggest otherwise. What vitamin B3 offers is an adjunctive layer — a systemic intervention targeting the molecular consequences of photodamage rather than its external cause.

Questions remain that dermatologists will want answered before broad adoption. Optimal dosing, duration of protective effect after discontinuation, and efficacy in distinct risk strata — including solid organ transplant recipients — continue to shape the research agenda. The VA's engagement with the topic suggests those questions may find institutional support, given the scale of skin cancer burden in the veteran population it serves.

As evidence accumulates, nicotinamide could move closer to a standardized place in chemoprevention protocols for high-risk patients, and VA researchers appear positioned to contribute meaningful data from one of the largest skin cancer populations under single-system care.